Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Interleukin 6 (IL-6) (plasma)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Inflammation
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Serum levels of IL-6, and inflammatory cytokine, are elevated in late onset AD.

What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)

  1. Dursun, E., Gezen-Ak, D., Hanağası, H., Bilgiç, B., Lohmann, E., Ertan, S., ... & Gündüz, A. (2015). The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. Journal of neuroimmunology, 283, 50-57. https://www.ncbi.nlm.nih.gov/pubmed/26004156

  2. Sharma, N., & Singh, A. N. (2016). Exploring biomarkers for Alzheimer’s disease. Journal of clinical and diagnostic research: JCDR, 10(7), KE01. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020308/

  3. Wu, Y. Y., Hsu, J. L., Wang, H. C., Wu, S. J., Hong, C. J., & Cheng, I. H. J. (2015). Alterations of the neuroinflammatory markers IL-6 and TRAIL in Alzheimer's disease. Dementia and geriatric cognitive disorders extra, 5(3), 424-434. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677720/